Cacti Asset Management LLC Acquires Shares of 25,000 Organon & Co. $OGN

Key Points

• Cacti Asset Management LLC made a new investment in Organon & Co. by acquiring 25,000 shares valued at approximately $246,000 during the second quarter.
• Organon & Co. recently reported an earnings per share (EPS) of $1.00 for the quarter, surpassing analysts' expectations of $0.94.
• Institutional investors own 77.43% of Organon & Co.’s stock, indicating significant confidence in the company by larger investment firms.

Cacti Asset Management LLC acquired a new position in shares of Organon & Co. (NYSE:OGN - Free Report) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 25,000 shares of the company's stock, valued at approximately $246,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. NBC Securities Inc. grew its stake in shares of Organon & Co. by 111,262.5% during the 1st quarter. NBC Securities Inc. now owns 8,909 shares of the company's stock worth $132,000 after purchasing an additional 8,901 shares during the period. Sequoia Financial Advisors LLC increased its holdings in Organon & Co. by 42.2% in the 1st quarter. Sequoia Financial Advisors LLC now owns 19,392 shares of the company's stock worth $289,000 after acquiring an additional 5,758 shares in the last quarter. M&T Bank Corp increased its holdings in Organon & Co. by 3.4% in the 1st quarter. M&T Bank Corp now owns 55,990 shares of the company's stock worth $833,000 after acquiring an additional 1,854 shares in the last quarter. Cetera Investment Advisers increased its holdings in Organon & Co. by 62.7% in the 4th quarter. Cetera Investment Advisers now owns 76,005 shares of the company's stock worth $1,134,000 after acquiring an additional 29,287 shares in the last quarter. Finally, GAMMA Investing LLC increased its holdings in Organon & Co. by 186.9% in the 1st quarter. GAMMA Investing LLC now owns 4,611 shares of the company's stock worth $69,000 after acquiring an additional 3,004 shares in the last quarter. Institutional investors and hedge funds own 77.43% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, BNP Paribas upgraded Organon & Co. to a "strong-buy" rating in a report on Thursday, May 22nd. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $17.33.

Organon & Co. Stock Down 0.5%

Shares of Organon & Co. stock traded down $0.05 on Tuesday, reaching $10.35. 3,698,690 shares of the company were exchanged, compared to its average volume of 3,422,680. Organon & Co. has a 1-year low of $8.01 and a 1-year high of $20.96. The company has a market cap of $2.69 billion, a P/E ratio of 2.95, a price-to-earnings-growth ratio of 0.95 and a beta of 0.60. The company has a debt-to-equity ratio of 11.98, a current ratio of 1.65 and a quick ratio of 1.13. The stock's 50 day moving average price is $9.65 and its 200-day moving average price is $10.79.

Organon & Co. (NYSE:OGN - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $1.00 EPS for the quarter, topping analysts' consensus estimates of $0.94 by $0.06. The business had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $1.55 billion. Organon & Co. had a return on equity of 163.88% and a net margin of 11.15%.The business's revenue for the quarter was down .8% on a year-over-year basis. During the same period in the previous year, the company posted $1.12 earnings per share. Organon & Co. has set its FY 2025 guidance at EPS. As a group, equities analysts forecast that Organon & Co. will post 3.68 EPS for the current year.

Organon & Co. Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, September 11th. Investors of record on Friday, August 15th were paid a dividend of $0.02 per share. The ex-dividend date was Friday, August 15th. This represents a $0.08 annualized dividend and a yield of 0.8%. Organon & Co.'s payout ratio is presently 2.97%.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.